stockrow
Friday 6 November 2026
Export CTXR’s income statement to Excel — free account
Citius Pharmaceuticals, Inc.
CTXR Healthcare Biotechnology
- EPS
- +57.5%
- Free cash flow
- −60.5%
Quarter to June 2026, against a year earlier
0.55
0.01
−1.79%
Follow CTXR
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 10 | 21 | 51 | +124.6% | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 | 0.0 pt | ||||||
| EBT | (8) | (10) | (13) | (16) | (18) | (23) | (33) | (32) | (39) | (39) | (58) | +18.7% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (8) | (10) | (13) | (16) | (18) | (23) | (34) | (33) | (39) | (40) | (58) | +19.0% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (57.24) | (47.36) | (29.25) | (19.25) | (11.25) | (5.75) | (5.75) | (5.50) | (5.97) | (3.38) | (2.13) | (27.0%) | ||||||
| Cash flow | (40.72) | (36.35) | (26.36) | (15.42) | (10.81) | (5.58) | (4.85) | (4.80) | (4.19) | (2.40) | (1.33) | (27.0%) | ||||||
| Capex | 0.00 | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | (40.72) | (36.36) | (26.36) | (15.42) | (10.81) | (5.58) | (4.85) | (4.80) | (4.19) | (2.40) | (1.33) | (27.0%) | ||||||
| Book value | 115.71 | 100.08 | 64.91 | 33.67 | 21.49 | 30.57 | 17.70 | 15.11 | 11.02 | 7.01 | 2.90 | (26.8%) | ||||||
| Shares, m | 0 | 0 | 0 | 1 | 2 | 4 | 6 | 6 | 7 | 11 | 20 | +61.9% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (6) | (8) | (11) | (12) | (17) | (24) | (28) | (29) | (28) | (27) | (35) | +18.2% | |||||
| Capex | — | 0 | — | — | 0 | 0 | — | — | — | — | 0 | +34.6% | ||||||
| Free cash flow | (6) | (8) | (11) | (12) | (17) | (24) | (28) | (29) | (28) | (27) | (35) | +18.2% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | (4) | 1 | 7 | 3 | 10 | 69 | 40 | 29 | (22) | (17) | (8) | +16.5% | |||||
| Net debt | 0 | (3) | (9) | (8) | (14) | (70) | (42) | (26) | (3) | (4) | (11) | +34.5% | ||||||
| Shareholders’ equity | 17 | 22 | 28 | 27 | 34 | 133 | 103 | 91 | 74 | 78 | 76 | +18.5% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (73.12) | (44.79) | (45.20) | (45.91) | (43.59) | (26.32) | (26.24) | (30.97) | (36.49) | (30.24) | (34.29) | +42.9 pt | |||||
| ROIC | (28.27) | (33.30) | (46.13) | (50.62) | (55.41) | (23.45) | (33.74) | (35.35) | (37.05) | (32.86) | (58.74) | (4.6) pt | ||||||
| ROE | (102.85) | (53.65) | (50.33) | (56.57) | (57.70) | (29.44) | (28.48) | (34.58) | (48.55) | (49.38) | (64.51) | +53.5 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 6 | 7 | 7 | 9 | 10 | 15 | 21 | 22 | 23 | 23 | — | +16.1% | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Latest quarter Jun 2026 · fundamentals updated 26 Oct 2026
Citius Pharmaceuticals, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| JSPR Jasper Therapeutics, Inc. | $15.6M | — (loss-making) | — | — | n/m | +55.74% (above 0%: growing) | 0.00% | 0.00% | Compare |
| NCEL NewcelX Ltd. | $15.6M | — (loss-making) | — | — | n/m | −87.71% (below 0%: shrinking) | 0.00% | — | Compare |
| ALLR Allarity Therapeutics, Inc. | $15.5M | — (loss-making) | — (loss-making) | — | n/m | +53.22% (above 0%: growing) | 100.00% | 0.00% | Compare |
| VAXX Vaxxinity, Inc. | $15.5M | — (loss-making) | — (loss-making) | −100.23% (below 0%: shrinking) | n/m | +17.00% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ABOS Acumen Pharmaceuticals, Inc. | $15.5M | — (loss-making) | — | — | n/m | +12.58% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CTXR Citius Pharmaceuticals, Inc. | $15.3M | — (loss-making) | — | — | n/m | −60.50% (below 0%: shrinking) | 67.07% | (785.39%) | |
| PLUR Pluri Inc. | $15.0M | — (loss-making) | — (loss-making) | −15.83% (below 0%: shrinking) | n/m | +25.03% (above 0%: growing) | 58.51% | (1,655.52%) | Compare |
| NEUP Neuphoria Therapeutics Inc. | $15.0M | — (loss-making) | — (loss-making) | −107.32% (below 0%: shrinking) | n/m | +133.86% (above 0%: growing) | 100.00% | 0.00% | Compare |
| MRKR MARKER THERAPEUTICS, INC. | $14.9M | — (loss-making) | — (loss-making) | −51.00% (below 0%: shrinking) | n/m | −97.84% (below 0%: shrinking) | 209.68% | 0.00% | Compare |
| Median of peers | $15.5M | — | — | −75.61% | — | +21.02% | 29.26% | 0.00% |
Pay and ownership Proxy statement filed 24 February 2026
Ownership
Directors and executive officers, together
4.99%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement